Global Direct-Acting Antiviral Medicines Market Trends, Analysis, Growth, and Forecast: 2018 to 2027
MarketResearch.biz delivers in-depth insights on the global direct-acting antiviral medicines market in its upcoming report titled, “Global Direct-Acting Antiviral Medicines Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global direct-acting antiviral medicines market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global direct-acting antiviral medicines market report has been segmented on the basis of drug class, sales channel, and region.
This report is based on synthesis, analysis, and interpretation of information gathered regarding the target market from various sources. Our analysts have analyzed the information and data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the market. In addition, an in-house study has been made of the global economic conditions and other economic indicators and factors to assess their respective impact on the market historically, as well as the current impact in order to make informed forecasts about the scenarios in future.
Hepatitis C virus is a small positive-strand RNA virus. This virus is a leading cause of liver diseases such as hepatocellular carcinoma and liver cirrhosis. Globally direct-acting antivirals (DAAs) have been proven to be safe and effective medicine against hepatitis C virus. DAAs helps to prevent life threatening complications, that are generates after hepatitis C virus attack on human body.
Increasing product development and launch of new direct-acting antiviral medicines across the globe is a major factor driving growth of the global direct-acting antiviral medicines market. For example, AbbVie Inc. is developing ABT-493 (a protease inhibitor) and ABT-530 (an NS5A inhibitor). Also, Gilead Sciences, Inc. is engaged in clinical trial and it FDC of sofosbuvir and GS-5816 (an NS5A inhibitor) are in phase III clinical trial.
Moreover, increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis is another factor supporting growth of the target market. According to World Health Organization (WHO), in 2015, viral hepatitis resulted in an around 1.34 million deaths globally, of which 400,000 were due to cirrhosis and liver cancer caused by chronic hepatitis C infection.
Furthermore, increasing support from government authorities as well as from social healthcare associations to spread awareness about hepatitis C virus and treatments to cure it is expected to propel growth of the global direct-acting antiviral medicines market in the forecast period. For instance, in 2016, World Health Assembly endorsed the Global Health Sector Strategy on viral hepatitis 2016–2021 for elimination of hepatitis B and hepatitis C by 2030.
However, poor access to direct-acting antiviral medicines for individuals who are suffering from chronic infection in emerging countries is a major factor restraining growth of the target market. Also, side effects of DAAs is expected to hamper growth of the global direct-acting antiviral medicines market up to a certain extent.
North America market dominates the global direct-acting antiviral medicines market in terms of revenue contribution as compared to that of markets in other regions. This is mainly attributed to availability of direct-acting antiviral medicines and high awareness among the patient about direct-acting antiviral medicines in the region. Europe accounts for second-largest revenue share contribution to the global direct-acting antiviral medicines market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to increasing focus of major market players for product penetration in countries in the region.
Moreover, increasing hepatitis C infection prevalence and incidence cases in countries in the Asia Pacific region is another factor expected to result in high demand for direct-acting antiviral medicines in the forecast period.
Global direct-acting antiviral medicines market segmentation, by drug class:
- NS3/4A Protease Inhibitors
- Nucleoside and Nucleotide NS5B Polymerase Inhibitors
- NS5A Inhibitors
- Non-Nucleoside NS5B Polymerase Inhibitors
Global direct-acting antiviral medicines market segmentation, by sales channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others (E-pharmacies, E-commerce, and Drug Stores)
Global direct-acting antiviral medicines market segmentation, by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2028 Revenue in US$
- AbbVie Inc.
- Bristol-Myers Squibb
- Merck & Co.
- Vertex Pharmaceuticals, Inc.
- Janssen Therapeutics
- Gilead Sciences, Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!